CytRx to Present at Rodman & Renshaw 12th Annual Healthcare Conference

LOS ANGELES--(BUSINESS WIRE)-- CytRx Corporation (Nasdaq: CYTR), a biopharmaceutical company specializing in oncology, today announced that President and Chief Executive Officer Steven A. Kriegsman and Chief Medical Officer Daniel Levitt, MD, Ph.D., will be presenting at the 12th Annual Rodman & Renshaw Healthcare Conference on Tuesday, September 14, at 9:35 a.m. Eastern time (6:35 a.m. Pacific time). The conference is being held at the New York Palace Hotel.

The CytRx presentation will address actions to advance the clinical development of the Company’s high-value oncology development pipeline, including a discussion of the recently initiated Phase 2 clinical trials to evaluate the efficacy and safety of bafetinib in patients with advanced prostate cancer and high-risk B-cell chronic lymphocytic leukemia, and plans to initiate up to four additional oncology clinical trials.

A live webcast of the presentation will be available at http://www.cytrx.com and a webcast replay will be archived on the Company's website for 90 days.

About CytRx Corporation

CytRx Corporation is a biopharmaceutical research and development oncology company engaged in the development of high-value human therapeutics. The CytRx oncology pipeline includes three programs in clinical development for cancer indications: bafetinib, tamibarotene and INNO-206. The Company is evaluating bafetinib in the ENABLE Phase 2 clinical trial in high-risk B-cell chronic lymphocytic leukemia (B-CLL) and the PROACT Phase 2 clinical trial in advanced prostate cancer, and plans to begin a Phase 1 trial in brain cancer. CytRx has announced plans to initiate up to three Phase 2 clinical trials with its oncology candidate INNO-206 as a treatment for pancreatic cancer, gastric cancer and soft tissue sarcomas. In addition, CytRx is developing two drug candidates based on its industry-leading molecular chaperone technology, which aims to repair or degrade misfolded proteins associated with disease. CytRx also maintains a 17% equity interest in publicly traded RXi Pharmaceuticals, Inc. (NASDAQ: RXII). For more information on the Company, visit http://www.cytrx.com.



CONTACT:

Investor Relations
Legend Securities, Inc.
Thomas Wagner
800-385-5790 x152
718-233-2600 x152
[email protected]

KEYWORDS:   United States  North America  California  New York

INDUSTRY KEYWORDS:   Health  Biotechnology  Oncology  Pharmaceutical  Research  Science

MEDIA:

Logo
 Logo

Suggested Articles

Zentalis is coming out of stealth with an $85 million series C, which will propel its lead programs into pivotal trials and broaden its pipeline.

The planned takeover centers on ARQ 531, a BTK inhibitor that triggered durable responses in patients with B-cell malignancies.

At ASH, Dana-Farber researchers presented promising preclinical data on AMG 701, Amgen's long-lasting BiTE for multiple myeloma, but rivals loom.